43.19
price up icon0.47%   0.20
 
loading
前日終値:
$42.99
開ける:
$42.83
24時間の取引高:
1.52M
Relative Volume:
1.00
時価総額:
$5.06B
収益:
$3.22M
当期純損益:
$-576.40M
株価収益率:
-8.0279
EPS:
-5.38
ネットキャッシュフロー:
$-407.05M
1週間 パフォーマンス:
-4.93%
1か月 パフォーマンス:
-8.98%
6か月 パフォーマンス:
-17.48%
1年 パフォーマンス:
-38.40%
1日の値動き範囲:
Value
$41.70
$43.33
1週間の範囲:
Value
$41.70
$48.43
52週間の値動き範囲:
Value
$40.53
$75.71

Cytokinetics Inc Stock (CYTK) Company Profile

Name
名前
Cytokinetics Inc
Name
セクター
Healthcare (1166)
Name
電話
(650) 624-3000
Name
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
職員
0
Name
Twitter
@Cytokinetics
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
CYTK's Discussions on Twitter

CYTK を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CYTK
Cytokinetics Inc
43.19 5.06B 3.22M -576.40M -407.05M -5.38
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-07 開始されました Citigroup Buy
2025-01-22 開始されました Stifel Buy
2024-11-08 開始されました RBC Capital Mkts Outperform
2024-08-13 ダウングレード Goldman Buy → Neutral
2024-01-24 ダウングレード UBS Buy → Neutral
2024-01-05 ダウングレード Morgan Stanley Overweight → Equal-Weight
2023-11-09 開始されました Goldman Buy
2023-11-07 開始されました B. Riley Securities Buy
2023-08-15 開始されました SVB Securities Outperform
2023-02-17 開始されました BofA Securities Neutral
2022-12-23 繰り返されました Needham Buy
2022-12-20 開始されました Truist Buy
2022-10-11 開始されました UBS Buy
2022-01-28 開始されました Goldman Buy
2021-12-22 開始されました Oppenheimer Outperform
2021-12-10 開始されました JP Morgan Overweight
2021-10-07 開始されました Jefferies Buy
2021-03-12 開始されました Wolfe Research Outperform
2021-02-18 開始されました Barclays Overweight
2021-01-20 繰り返されました H.C. Wainwright Buy
2020-10-29 開始されました Goldman Neutral
2020-07-10 開始されました Raymond James Strong Buy
2020-05-05 開始されました Mizuho Buy
2020-04-09 アップグレード Morgan Stanley Equal-Weight → Overweight
2018-09-21 開始されました Cantor Fitzgerald Overweight
2018-09-10 再開されました Morgan Stanley Equal-Weight
2017-11-22 繰り返されました Morgan Stanley Overweight
2017-11-22 ダウングレード Needham Strong Buy → Buy
2017-11-21 繰り返されました H.C. Wainwright Buy
2017-07-31 開始されました Morgan Stanley Overweight
2017-03-08 開始されました Rodman & Renshaw Buy
2017-02-06 アップグレード Needham Buy → Strong Buy
2016-12-16 開始されました Cantor Fitzgerald Overweight
2016-07-28 繰り返されました Needham Buy
2015-11-10 繰り返されました FBR Capital Outperform
2015-11-09 繰り返されました ROTH Capital Buy
2015-07-24 繰り返されました MLV & Co Buy
2014-12-31 繰り返されました ROTH Capital Buy
2014-11-04 アップグレード MLV & Co Hold → Buy
2014-04-28 繰り返されました Needham Buy
すべてを表示

Cytokinetics Inc (CYTK) 最新ニュース

pulisher
06:44 AM

Cytokinetics Announces Data From Phase 1 Study of CK-4021586 - Marketscreener.com

06:44 AM
pulisher
Mar 25, 2025

Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025
pulisher
Mar 24, 2025

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? - Nasdaq

Mar 24, 2025
pulisher
Mar 20, 2025

Cytokinetics Launches EARTH-HCM: An Interactive Tool for Understanding Hypertrophic Cardiomyopathy and Improving Access to Care - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community - The Manila Times

Mar 20, 2025
pulisher
Mar 19, 2025

Cytokinetics EVP Malik sells $87,160 in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Cytokinetics EVP Malik sells $87,160 in stock - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Cytokinetics announces inducement grants under Nasdaq listing rule 5635(C)(4) -March 18, 2025 at 04:15 pm EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Cytokinetics Strengthens Workforce: 13 New Hires Secure Strategic Equity Awards - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

H.C. Wainwright maintains Buy on Cytokinetics, $120 target By Investing.com - Investing.com UK

Mar 18, 2025
pulisher
Mar 17, 2025

Cytokinetics Executives Engage in Multiple Stock Transactions - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Cytokinetics Incorporated: Aficamten's Differentiated Profile and Market Potential Is Powering Our Hopefulness! - Smartkarma

Mar 17, 2025
pulisher
Mar 17, 2025

UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating -March 17, 2025 at 11:27 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual ... - NRToday.com

Mar 17, 2025
pulisher
Mar 15, 2025

Cytokinetics’ EVP sells $4,500 in stock By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 15, 2025

Cytokinetics EVP Andrew Callos sells $4,500 in stock By Investing.com - Investing.com UK

Mar 15, 2025
pulisher
Mar 14, 2025

Cytokinetics’ EVP sells $4,500 in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 13, 2025

Cytokinetics EVP Callos Andrew sells shares for $1.17 million By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Cytokinetics EVP Callos Andrew sells shares for $1.17 million - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Charles Schwab Investment Management Inc. Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Cytokinetics at Barclays Healthcare Conference: Strategic Launch Plans By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 11, 2025

Cytokinetics at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 10, 2025

Citi maintains Cytokinetics stock Buy rating, $86 target By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Why Have Cytokinetics Stocks Plummeted? - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics maintains expectation For Differentiated Label & Risk Mitigation Profile for Aficamten if approved By FDA - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics Completes Midcycle Review with FDA for Aficamten - TipRanks

Mar 10, 2025
pulisher
Mar 09, 2025

Robert I. Blum Sells 16,970 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

B. Riley Brokers Reduce Earnings Estimates for Cytokinetics - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook - sharewise

Mar 08, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Fady Ibraham sells $356,025 in stock By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Andrew Callos sells $144,565 in stock By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Andrew Callos sells $144,565 in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics CEO Robert Blum sells shares worth $737,176 - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Fady Ibraham sells $356,025 in stock - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics Executives Engage in Stock Transactions - TradingView

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics CEO Robert Blum sells shares worth $737,176 By Investing.com - Investing.com UK

Mar 07, 2025
pulisher
Mar 07, 2025

Morgan Stanley raises Cytokinetics stock to Overweight, $67 target By Investing.com - Investing.com UK

Mar 07, 2025
pulisher
Mar 07, 2025

What is B. Riley’s Forecast for Cytokinetics Q1 Earnings? - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Cytokinetics assumed with an Overweight at Morgan Stanley - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Cytokinetics Positioned for Growth: Buy Rating Backed by Aficamten’s Market Potential and Upcoming PDUFA Date - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Cytokinetics Executives Cash In: Massive Stock Sales Unveiled! - TipRanks

Mar 06, 2025
pulisher
Mar 05, 2025

Insider Sell Alert: Fady Malik Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus.com

Mar 05, 2025
pulisher
Mar 05, 2025

Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus.com

Mar 05, 2025

Cytokinetics Inc (CYTK) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Cytokinetics Inc (CYTK) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Malik Fady Ibraham
EVP Research & Development
Mar 18 '25
Sale
43.58
2,000
87,160
140,455
Callos Andrew
EVP, Chief Commercial Officer
Mar 17 '25
Sale
44.38
2,775
123,154
34,888
Malik Fady Ibraham
EVP Research & Development
Mar 17 '25
Sale
44.38
4,389
194,784
101,005
Blum Robert I
President & CEO
Mar 17 '25
Sale
44.38
12,648
561,318
326,533
Blum Robert I
President & CEO
Mar 17 '25
Sale
44.65
25,000
1,116,250
339,181
Callos Andrew
EVP, Chief Commercial Officer
Mar 17 '25
Option Exercise
23.26
20,900
486,134
58,563
Callos Andrew
EVP, Chief Commercial Officer
Mar 17 '25
Sale
45.14
20,900
943,426
37,663
Callos Andrew
EVP, Chief Commercial Officer
Mar 14 '25
Option Exercise
23.26
100
2,326
37,763
Callos Andrew
EVP, Chief Commercial Officer
Mar 14 '25
Sale
45.00
100
4,500
37,663
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):